Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
MarketScreener,
(Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer…